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Novelty and Impact: 
We evaluated the associations between breast cancer risk factors and levels of 
histologic grade and proliferation among 5,905 hormone receptor positive (HR+) 
invasive breast tumors and 26,281 controls. We found associations between nulliparity 
and highly proliferative tumors; obesity and high grade tumors; and current use of 
combined hormone therapy and low grade tumors. These findings provide insights into 
etiologic heterogeneity, and could have implications for risk prediction of aggressive 
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Limited epidemiological evidence suggests that the etiology of hormone receptor 
positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. 
We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 
controls from 11 epidemiological studies. Proliferation was determined by centralized 
automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence 
intervals (CI) and pvalues for casecase and casecontrol comparisons for risk factors 
in relation to levels of grade and quartiles (Q1Q4) of KI67 were estimated using 
polytomous logistic regression models. Casecase comparisons showed associations 
between nulliparity and high KI67 [OR (95% CI) for Q4 vs Q1 = 1.54 (1.22, 1.95)]; 
obesity and high grade [grade 3 vs 1 = 1.68 (1.31, 2.16)]; and current use of combined 
hormone therapy (HT) and low grade [grade 3 vs 1 = 0.27 (0.16, 0.44)] tumors. In case
control comparisons, nulliparity was associated with elevated risk of tumors with high 
but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs 0.83 (0.60, 1.14) 
for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors 
[1.55 (1.17, 2.06) for grade 3 vs 0.88 (0.66, 1.16) for grade 1]; and HT with low but not 
high grade tumors [3.07 (2.22, 4.23) for grade 1 vs 0.85 (0.55, 1.30) for grade 3]. 
Menarcheal age and family history were similarly associated with HR+ tumors of 
different grade or KI67 levels. These findings provide insights into the etiologic 
heterogeneity of HR+ tumors.  
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Breast cancer is a heterogeneous disease at the morphological, molecular and genomic 
level, defining subtypes with distinct biological and clinical behavior (13).  Expression 
of hormone receptors (HR; i.e. estrogen receptor (ER) or progesterone receptor (PR)) 
distinguishes two classes of tumors thought to derive from different cells of origin: 
HR+ tumors deriving from luminal epithelial cells and HR– from basal/myoepithelial 
cells (1). In Western populations, HR+ tumors occur more commonly (~70% of 
tumors) and have a later age at onset and better shortterm prognosis than HR tumors 
(4, 5). While epidemiological studies have shown that these two subtypes may have 
distinct risk factor associations (69), little is known about etiologic heterogeneity 
within HR+ tumors (10, 11).   
Histologic grade is an important indicator of tumor aggressiveness that reflects three 
features including tubule formation, nuclear pleomorphism, and mitotic count, which is 
directly related to proliferation (12). Due to the latter feature, it is highly correlated 
with KI67 (a marker of proliferation) and both have been used to identify surrogates for 
two HR+ tumors identified by expression tumor profiling studies, i.e. luminal A and 
luminal B subtypes (1315). Epidemiological studies suggest that these two subtypes 
could have differential associations with risk factors (10, 16). However, although 
correlated, histologic grade and KI67 reflect different biological features of tumors that 
could be of etiological relevance. Unlike grade which encompasses both differentiation 
and proliferation, KI67 is expressed only during the proliferative phases of the cell
cycle and is one of the most commonly used markers of proliferation (1719). Its 
function is not fully understood but it is thought to mediate assembly of the peri
chromosomal compartment in human cells (20).  
Accumulating epidemiological data suggest that breast cancer risk factors may be 
distinctly associated with grade and KI67 (2123). Three previous studies found 
associations between high BMI and high levels of histologic grade but not KI67 (21
23) whilst younger age at onset of breast cancer and being of AfricanAmerican 
ethnicity were reportedly associated with high levels of KI67 but not histologic grade 
(23). These studies were caseseries with limited sample sizes (346 to 668 cases), and 
were based on semiquantitative visual scores for KI67. This scoring approach is 
characterized by poor interobserver reproducibility (24, 25) and offers limited 
opportunities for evaluating dose response relationships. Thus, studies with larger 
sample sizes and standardized quantitative measures of KI67 across studies are needed 
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to evaluate the relationship between breast cancer risk factors and HR+ tumors defined 
by their levels of proliferation and histologic grade. 
In this report, we pooled risk factor data from a consortium of breast cancer studies to 
examine the relationship of breast cancer risk factors with subtypes of HR+ tumors 
defined by levels of histologic grade and KI67 expression, determined by centralized 




A total of 5,905 HR+ invasive breast cancer cases and 26,281 controls were pooled 
from 11 epidemiological casecontrol studies with TMAs and risk factor information in 
the Breast Cancer Association Consortium (BCAC). Study populations were from 
Europe, Australia and North America. Details of the contributing studies including 
designs, country of location, method of recruitment, age range, sources and eligibility 
of cases and controls are provided in 	

	. In brief, this analysis 
comprised 11 casecontrol studies (one of them (UKBGS) nested within a prospective 
cohort study). Six studies (CNIO, MCBCS, ORIGO, RBCS, SEARCH and kConFab) 
were of hospitalbased or mixed study designs (considered ‘nonpopulationbased’ 
studies), whilst five studies (ESTHER, KBCP, MARIE, PBCS and UKBGS) were 
populationbased. All participants in each of the study groups provided written 
informed consent and all studies gained approval from local ethics committees.    


Data on risk factors were derived from questionnaires that were administered to 
participants at recruitment in each of the participating BCAC studies. Harmonization, 
central querying and quality checks on these data were performed by investigators at 
the German Cancer Research Institute, Heidelberg. The current analysis included risk 
factors for which there is evidence in the literature to suggest a heterogeneous 
relationship with clinicopathological characteristics and for which we had data. In this 
regard, five risk factors were identified  age at menarche, parity, body mass index 
(BMI), use of combined hormone therapy (HT) and family history of breast cancer. 
	

	 shows the number of cases and controls from each study with 
risk factor information.  


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Data on hormone receptor status were obtained from clinical records. Levels of 
histologic grade were assigned by local study pathologists in the respective study 
groups. Tumors were graded as 1 (low grade or welldifferentiated), 2 (intermediate 
grade or moderately differentiated) and 3 (high grade or poorly differentiated).  The 
extent of proliferation in breast cancer tissues was determined using measures of KI67. 
Scores were centrally generated at the Institute of Cancer Research (ICR) in London by 
using a digital image analysis protocol that was developed for the quantification of 
KI67 in breast cancer TMAs as previously described (26).  In brief, a total of 166 
TMAs were collected for evaluation from the participating BCAC studies. These were 
stained using a standard protocol of (Dako) MIB1 antibody diluted 1/50 and visualized 
using the Dako REAL kit (K5001). Automated scoring was performed using the Ariol 
machine (Leica Biosystems), which has functionality that allows for the discrimination 
of malignant and nonmalignant nuclei using shape and size characteristics as well as 
the automatic detection of KI67 positive and negative malignant nuclei using color 
deconvolution. The algorithm was used to generate quantitative (0100% positive cells) 
KI67 scores. As previously reported (26), Ariol scores showed good agreement with 
standardized pathologist’s scores. Subsequently, automated KI67 scores were merged 
with other risk factor and pathological characteristics. The majority of the 5,905 cases 
had complete data on KI67 (83%) or grade (76%) and at least one risk factor (see 
	

	 for details). All pathology data were harmonized and quality 






Participant ages at diagnosis/ages at interview were categorized into five classes (<40, 
4049, 5059, 6069 and ≥ 70). Age at menarche was categorized into four classes (≤ 
12, 13, 14, ≥ 15). Parity was defined as nulliparous or parous for casecase and case
control comparisons. For BMI, three welldefined categories were used (normal <25 
kg/m2; overweight 2530 kg/m2 and obese >30 kg/m2) and the casecontrol analysis was 
conducted for groups of women stratified according to age (<50 years and ≥50 years) 
as a surrogate for menopausal status. This was done to account for previously reported 
differences in the association between BMI and breast cancer risk by menopausal 
status. For the casecase comparisons, BMI was not differentially related to tumor 
grade/KI67 levels by age categories (proxy for menopausal status); as a result, case
case analysis was not stratified according to age. HT use was categorized into those 
who never used HT, former users and current users. Due to very small numbers of 
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those who reported using estrogen only formulations, our analysis involved only those 
women who took combined estrogen and progesterone formulations. Family history of 
breast cancer in a firstdegree relative was categorized as yes (if present) or no (if not 
present). Frequency tables were used to assess the distribution of the risk factors among 
cases and controls stratified by study design. To test for differences in the distribution 
of risk factors for cases and controls by study design, we created a dummy variable for 
design and modelled this as the outcome with the different risk factors as predictors. 
Box plots and nonparametric KruskalWallis equality of median test were used to 
assess the distribution of KI67 across categories of histologic grade, overall and by 
study.  
We constructed a polytomous unconditional logistic regression model for each risk 
factor variable, and performed casecase and casecontrol comparisons within the same 
model. For casecase comparisons, odds ratios (OR), 95% confidence intervals and p
values for the associations between breast cancer risk factors [menarche (≤ 12 vs ≥ 15 
years); parity (nulliparous vs parous); BMI (2530 kg/m2 and >30 kg/m2 vs <25kg/m2, 
respectively); HT (former and current vs never, respectively); family history (yes vs 
no)] and quartiles of KI67 [Q1 (base category), <25th  percentile (01.49%); Q2, 2550th 
percentile (1.504.29%); Q3, >50th–75th percentile (4.3010.40%); Q4, >75th percentile 
(>10.40%)] and histologic grade [grade 1 (base category), 2, 3] were estimated. For 
casecontrol comparisons, an interaction term between study design (populationbased 
versus nonpopulation based) and the risk factor of interest was included to obtain 
estimates of association by study design. Because of previously reported biases in case
control ORs estimated from nonpopulation based studies (9), only casecontrol ORs 
from populationbased studies are presented in tables. However, ORs for casecase 
comparisons and corresponding tests are based on data from all cases (i.e. both from 
populationbased and nonpopulation based studies). Metaanalyses of studyspecific 
casecase and casecontrol ORs were performed to test for betweenstudy heterogeneity 
in the OR estimates.  
We examined doseresponse relationships between risk factors and levels of KI67, by 
using the median % positive cells in each quartile of KI67 as constraints in an ordered 
polytomous logistic regression model (27). To determine if the relationships between 
nulliparity, obesity and current use of combined HT are distinct, we applied a 2stage 
metaregression model (28). In the first stage of the 2stage metaregression model, we 
performed a polytomous logistic regression analyses for subtypes of HR+ breast cancer 
defined by crossclassification of levels (Q1Q4) of KI67 and histologic grade (low 
(grade1) and high (grades 2 & 3)). In the second stage, we modelled the subtype
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specific log odds ratios and standard errors using KI67 and grade. This approach 
allowed us to evaluate if the risk factorsubtype associations are different across 
subtypes defined by KI67 whilst controlling for grade, and viceversa. Also, by 
including an interaction term between KI67 and grade we were able to examine if the 
relationship between risk factors and subtypes defined by levels of KI67 were modified 
by grade or vice versa.  
Analysis on each risk factor was limited to studies that provided information on that 
risk factor. Missing values were addressed by creating indicators for missing values in 
our models. As sensitivity analysis, all risk factors were mutually adjusted for in a 
multivariate model comprising data from three studies with information on the five risk 
factors that were evaluated. All analyses, including casecase and casecontrol 
comparisons, were adjusted for age and study. All statistical tests were twosided and 
performed using Stata statistical software version 13.1. 
Results    

	 shows a description of the characteristics of the study participants based on 
populationbased (N = 5 studies) and nonpopulationbased (N = 6 studies) designs. 
While the distribution of most risk factors in cases was similar by study design, most 
risk factors showed different distributions in population and nonpopulation based 
studies.    
Overall, the median and mean positive cells stained for KI67 was 4.2% and 8.2%, 
respectively. Most tumors were of intermediate grade (52%), followed by low grade 
(26%) and high grade (22%) tumors. As expected, grade 1 tumors had lower KI67 
scores compared with grades 2 and 3 tumors [median and mean = 3% and 6.3%; 4.3% 
and 8%; 7% and 11% for grades 1, 2 and 3 tumors, respectively]. A similar pattern of 
















As shown in 
	 , we observed that compared with their normal weight 
counterparts, tumors occurring amongst overweight and obese women were more likely 
to be of higher (grades 2 and 3) than lower (grade 1) grade. Specifically, we observed 
overweight women to have 33% (95% CI = 1.13, 1.58) and 23% (95% CI = 1.00, 1.52) 
increased odds of developing grades 2 and 3 than grade 1 tumors, respectively. 
Similarly, high grade tumors were more likely to occur amongst obese than normal 
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weight women [vs grade 1, OR (95% CI) = 1.67 (1.13, 2.05); pvalue = 0.001 for grade 
2 and 1.68 (1.31, 2.16); pvalue = <0.001 for grade 3 tumors]. As shown in 
	
 
	 (, these associations were similar following stratification by 
tumor size (pvalue for interaction (P_interaction) = 0.52).  
Compared with women who never took HT, tumors occurring amongst current users of 
combined HT were less likely to be high than low grade [vs grade 1: OR (95% CI) = 
0.45 (0.32, 0.63); pvalue = <0.001 for grade 2 and 0.27 (0.16, 0.44); pvalue = <0.001 
for grade 3 tumors]. When we tested the associations between tumor grade, KI67 and 
morphology (ductal vs lobular) in relation to HT use, all three tumor features were 
associated with HT use in univariate models at pvalue <0.05. However, following 
mutual adjustment for all three features in a multivariable model, only histologic grade 
remained associated with HT use (OR (95% CI) = 0.45 (0.27, 0.76); pvalue = 0.003 
for grade 2 vs 1 and 0.25 (0.11, 0.57); pvalue = 0.001 for grade 3 vs 1). Furthermore, 
as shown in 	
 
	 (, HT use remained associated with low grade 
tumors regardless of tumor size (P_interaction = 0.78). Age at menarche, nulliparity, and 
family history of breast cancer in a firstdegree relative were not differentially related 
to HR+ tumors defined by levels of histologic grade. 
As shown in 
	, compared with tumors occurring among parous women, those 
occurring among nulliparous women were more likely to have higher KI67 expression 
and a statistically significant gradient was observed in this relationship [OR (95% CI) 
vs. KI67 Q1 = 1.14 (1.06, 1.23) for KI67 Q2; 1.22 (1.09, 1.37) for KI67 Q3 and 1.50 
(1.20, 1.88) for KI67 Q4; pvalue for trend 0.001)]. There was weaker or no evidence 
for associations with KI67 levels for age at menarche, BMI, HT, and family history of 











Casecontrol comparisons in populationbased studies showed an elevated risk of HR+ 
tumors with high levels of tumor proliferation among nulliparous women (and 
in 	
 
	 ,- pvalue for betweenstudy heterogeneity = 0.78). 
Furthermore, as shown in and in 	

	&, obesity amongst 
women older than 50 years of age was associated with elevated risks of high but not 
low grade tumors (pvalue for betweenstudy heterogeneity = 0.76). Among women 
younger than 50 years of age (	

	 .), we observed obesity to be 
associated with reduced risk of breast cancer across all levels of histologic grade, this 
association was however weaker for grades 2 and 3 than grade 1 tumors (pvalue for 
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betweenstudy heterogeneity = 0.72). Current use of combined HT was associated with 
an elevated risk of low but not high grade tumors ( and in 	


	.; pvalue for betweenstudy heterogeneity = 0.15). In multivariate analyses with 
mutual adjustment for the five risk factors that were evaluated in addition to age and 
study group, nulliparity remained significantly associated with high but not low KI67 
expressing tumors [OR (95% CI) = 1.33 (1.02, 1.74); pvalue = 0.03 for KI67 Q4 and 
0.85 (0.57, 1.25); pvalue = 0.40 for KI67 Q1]. Obesity among women ≥ 50 years of 
age remained significantly associated with high but not low grade tumors [OR (95% 
CI) = 1.50 (1.04, 2.18); pvalue = 0.03 for grade 3 and 0.82 (0.58, 1.15); pvalue = 0.26 
for grade 1]. Current use of combined HT remained significantly associated with low 
but not high grade tumors [3.04 (2.19, 4.21); pvalue <0.001 for grade 1 and 0.89 (0.58, 
1.38); pvalue = 0.61 for grade 3].    
When we examined the associations between nulliparity, obesity, HT use and subtypes 
of HR+ tumors defined by crossclassification of levels of KI67 and histologic grade 
(
	 (), we observed nulliparity to be more strongly associated with tumors 
expressing higher levels of KI67 and this association remained significant after 
accounting for grade (pvalue = 0.04) and was not modified by grade (P_interaction = 
0.37). Grade was determined to be the primary tumor characteristic associated with 
obesity (pvalue = 0.03) and this was regardless of KI67 levels (P_interaction = 0.59). 
Furthermore, HT use was more strongly associated with subtypes characterized by 
being low grade. We observed grade, not KI67, to be the primary tumor characteristic 
associated with HT use (pvalue = 0.008) and there was no evidence to suggest that this 
association is dependent on levels of KI67 in the tumor (P_interaction = 0.48). 
Discussion 
Findings from analyses including almost 6000 cases with HR+ tumors provide 
evidence for heterogeneity within these tumors by histologic grade and level of 
proliferation. Nulliparity was primarily associated with risk of HR+ tumors with high 
levels of proliferation defined by KI67; whilst BMI and HT were associated with risk 
of high and low grade HR+ tumors, respectively.  
Epidemiological studies have shown that nulliparity is more consistently associated 
with increased risk for HR+ than HR breast cancer (7, 9, 29, 30). Our analyses indicate 
that nulliparity is primarily associated with an elevated risk of HR+ tumors with high 
levels of proliferation, which is consistent with findings from a previous prospective 
study (31). These findings could reflect parityrelated mechanisms influencing the 
proliferative potential of mammary epithelial cells via the induction of terminal 
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differentiation (32). This is in keeping with animal studies that show pregnancy
mediated persistent increase in the differentiated state of the mammary gland, in 
addition to reduction in epithelial cell proliferation mediated, at least in part, by the 
downregulation of growth factors and the upregulation of growthinhibitory 
molecules (33).   
Postmenopausal obesity is associated with an elevated risk of breast cancer that is more 
consistent for the HR+ subtype (34). Consistent with our findings, previous studies 
have reported a higher frequency of high grade (2123) and large (35) tumors amongst 
obese women; however, it is unclear whether these reported observations are driven by 
grade, tumor size or proliferation since these features are correlated but seldom studied 
simultaneously. Our analyses indicate that grade is the primary tumor characteristics 
related to obesity. Several biological pathways involving estrogen metabolism (36, 37), 
insulin resistance, inflammation and altered adipokine and cytokine production, have 
been proposed to mediate the obesitycancer link (38). It is plausible that obesity
induced systemic and/or intratumoral inflammation may contribute to the emergence, 
via cancer immunoediting (39) and/or noncellular mechanisms (40), of aggressive 
forms of breast tumors. Further studies will be required to unravel the mechanisms 
underpinning the relationship between BMI and breast cancer histopathological 
characteristics.  
Use of combined HT has been shown in epidemiological studies to be consistently 
associated with tumors with favorable biological profile including HR+, lobular or 
tubular morphology, small and low grade tumors (35, 4144). In line with these reports, 
we found an association between HT and HR+ low grade tumors, that is independent of 
KI67. The current analysis includes data from a previously published study (PBCS) 
where we reported an association with low grade but did not measure KI67 (35). HT 
use is known to be more strongly associated with the invasive lobular cancers, typically 
low grade and low proliferating (45, 46), than with nospecialtype (NST) invasive 
ductal carcinomas, which represent 5070% of all invasive cancers. However, our 
analyses indicated that HT use predisposes similarly to low grade tumors, 
independently of morphology. More active screening among HT users may lead to 
detection of tumors with more favorable features including being low grade. Due to 
lack of information on screening history and mode of detection, we were unable to 
directly examine the impact of screening on our findings. We did this indirectly, by 
using tumor size as proxy for mode of detection and observed HT to be associated with 
low grade tumors regardless of tumor size (pvalue for heterogeneity = 0.78). Thus, our 
findings could reflect a biological role for HT in influencing tumor behavior; however, 
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further studies directly accounting for screening history and mode of detection will be 
needed to clarify relationships. Postmenopausal obesity has been shown to increase the 
risk of breast cancer only among women who do not take HT (47, 48). We stratified 
our casecase analyses by HT use and our results remained essentially the same even 
though numbers of cases were small.  
An important strength of this analysis is that we centrally generated continuous 
measures of tumor proliferation using automated digitalpathology algorithms to score 
KI67. As we previously showed, this provides standardized, highly reproducible 
measures of KI67 with good agreements with pathologists’ quantitative and semi
quantitative scores (26). This allowed us to evaluate doseresponse relationships using 
quartiles, rather than arbitrary dichotomous categories of tumor proliferation. 
Additionally, data on other pathology markers enabled us to evaluate breast cancer risk 
factors in relation to both KI67 and grade in the context of tumor size and morphology.  
KI67 scores were obtained from TMAs that are generally lower than those obtained on 
whole sections (49). Additionally, we used an automated system to generate KI67 
scores that are usually lower than visual scores, regardless of whether measurement 
was made on TMAs or whole sections (26, 50). Thus, our scores for proliferation were 
lower than what is typically obtained for whole sections or following visual scoring on 
TMAs. Nonetheless, measurements from different sources are generally well correlated 
and unlikely to substantially affect the ranking of cases in relation to levels of KI67 
used in our analyses. Measurement error is a notable limitation for KI67 but automated 
methods are highly reproducible and show adequate accuracy in relation to 
standardized pathologists’ scores (26, 51). Furthermore, measurement error is unlikely 
to be differential with respect to risk factors, and therefore it would tend to under 
rather than overestimate odds ratios. Histologic grade tends to have low 
reproducibility within and between pathologists (52), however, this error is also likely 
to be nondifferential with respect to risk factors. Moreover, the consistency of our 
results with those of others who have assessed breast cancer risk factors in relation to 
KI67 and grade together (2123, 31), suggest that measurement error is unlikely to 
explain our findings.   
Our analyses comprised multiple studies with different study designs, including 
population and nonpopulationbased studies: nonpopulationbased studies are 
particularly prone to biases in casecontrol measures of association since the 
distribution of exposures amongst controls often does not reflect that in the source 
population for the cases. To address this, we limited casecontrol comparisons to 
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populationbased studies only. Tests of heterogeneity of associations by study revealed 
no evidence of heterogeneity of effect estimates for both casecontrol and casecase 
comparisons. Missing data on risk factors was another limitation in this study, 
particularly for casecontrol comparisons. To address this, we limited the analysis for 
each risk factor to studies with data on that risk factor in both cases and controls and 
used the conventional approach of creating indicators for missing values on each risk 
factor in our regression models. As sensitivity analyses, we performed multivariate 
analyses with mutual adjustment for all five risk factors in three studies with complete 
information on all covariates and our results remained essentially the same.  
In conclusion, our findings indicate that the associations between parity, BMI, use of 
combined HT and risk of HR+ tumors are heterogeneous depending on the levels of 
histologic grade and proliferation, indicated by KI67. Although correlated, histologic 
grade and KI67 appear to be distinctly related to breast cancer risk factors. These 
results provide insights into heterogeneity of HR+ tumors that may be reflective of 
differences in etiological pathways; however, other factors not evaluated in this 
manuscript, such as screening, could play a role. Given that grade and proliferation are 
important prognostic factors in HR+ breast cancer, these findings could have 
implications for risk prediction of aggressive forms of HR+ tumors. Further studies 
accounting for multiple correlated tumor characteristics and screening are needed to 
enable better understanding of these relationships.   
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Figure 1: Case-control odds ratios (OR) and 95% confidence intervals (CI) 
for the associations between parity, BMI, use of combined HT and risk of 
HR+ tumors defined by levels of histologic grade and tumor proliferation, 
indicated by KI67 
Levels of KI67 defined by quartiles of expression (Q1, <25th percentile (01.49%); Q2, 25th – 
50th percentile (1.504.29%); Q3, 50th – 75th percentile (4.3010.40%); Q4, >75th percentile 
(>10.40%)). Histologic grade defined as: 1 = welldifferentiated; 2 = moderately differentiated; 
and 3 = poorly differentiated. All models were adjusted for age and study. No evidence was 
observed of betweenstudy heterogeneity in studyspecific OR estimates (pvalue > 0.05). For 
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    Population-based   Non-population-based 
Characteristic   Controls (No.) % Cases (No.) %   Controls (No.) % Cases (No.) % 
Age, years                     
<40   252 2.2 42 2.1   590 4.7 249 6.7 
40-49   1247 10.9 293 14.4   2135 17.0 905 24.3 
50-59   3999 34.9 682 33.6   4696 37.4 1456 39.1 
60-69   4720 41.1 708 34.9   3662 29.2 882 23.7 
≥ 70   1256 10.9 303 14.9   1464 11.7 233 6.3 
                      
Age at menarche, years                   
≤12   2140 26.2 522 27.8   3491 40.5 1123 42.9 
13   1838 22.5 431 22.9   2263 26.3 640 24.4 
14   2034 24.9 498 26.5   1617 18.8 471 18.0 
≥15   2168 26.5 427 22.7   1245 14.4 385 14.7 
                      
Parity                     
None   1221 13.5 310 15.6   1437 16.4 396 14.3 
1-2   5941 65.6 1331 66.9   4495 51.3 1484 53.5 
3-4   1726 19.0 312 15.7   2460 28.1 798 28.8 
≥5   175 1.9 37 1.9   363 4.1 94 3.4 
                      
BMI, kg/m
2
                     
Among women <50 years                   
<25   542 44.4 194 51.1   672 49.7 461 52.3 
25-30   431 35.3 144 37.9   387 28.6 273 31.0 
>30   249 20.4 42 11.1   292 21.6 147 16.7 
Among women ≥ 50 years                   
<25   2775 35.6 472 29.5   1998 34.5 646 37.4 
25-30   3028 38.9 641 40.1   2366 40.9 679 39.3 
>30   2005 25.7 486 30.4   1419 24.5 401 23.2 
                      
Combined HT Use                     
Never   4836 70.7 1000 73.4   1070 74.9 196 75.1 
Former   849 12.4 117 8.6   238 16.7 29 11.1 
Current   1154 16.9 245 18.0   120 8.4 36 13.8 
                      
Family History                     
No   8023 90.2 1707 87.4   7778 88.6 1997 76.9 
Yes   874 9.8 247 12.6   1004 11.4 599 23.1 
                      
 
The study population comprised of 11 studies participating in the Breast Cancer Association Consortium (see supplementary 
Table 1 for details of the individual studies) with population (ESTHER, KBCP, MARIE, PBCS, UKBGS) and non-population (CNIO, 
kConFab, MCBCS, ORIGO, RBCS, SEARCH) based designs. In a model with study design as the outcome: for controls, the 
distribution of all the risk factors differed by design (p-value <0.05); for cases, only menarche and family history were different by 
design.   
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    Histologic Grade   
  Grade 1 (comparison group) Grade 2 Grade 3 
Risk factor    N N OR (95% CI) p-value N OR (95% CI) p-value 
Menarche                  
≥ 15 years    183 417 1.00 (referent)   157 1.00 (referent)   
14 years  218 497 1.01 (0.80, 1.28) 0.93 186 0.99 (0.74, 1.33) 0.97 
13 years   266 529 0.96 (0.76, 1.20) 0.71 192 0.89 (0.67, 1.18) 0.42 
≤ 12 years   363 836 1.09 (0.87, 1.35) 0.46 299 0.96 (0.73, 1.26) 0.77 
                  
Parity                 
Parous    902 2089 1.00 (referent)   745 1.00 (referent)   
Nulliparous   165 322 0.86 (0.70, 1.06) 0.16 157 1.09 (0.86, 1.40) 0.46 
                  
BMI                 
< 25 kg/m
2
   454 832 1.00 (referent)   332 1.00 (referent)   
25-30 kg/m
2
   385 929 1.33 (1.13, 1.58) 0.001 326 1.23 (1.00, 1.52) 0.05 
>30 kg/m
2
   202 596 1.67 (1.13, 2.05) <0.0001 212 1.68 (1.31, 2.16) <0.0001 
                  
Combined HT use                  
Never   169 545 1.00 (referent)   156 1.00 (referent)   
Former   33 76 0.71 (0.45, 1.12) 0.15 17 0.47 (0.25, 0.89) 0.02 
Current   84 134 0.45 (0.32, 0.63) <0.0001 29 0.27 (0.16, 0.44) <0.0001 
                  
Family history                  
No   844 1918 1.00 (referent)   399 1.00 (referent)   
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    KI67    
  Q1 (Comparison group) Q2 Q3 Q4  
Risk factor    N N OR (95% CI) p-value N OR (95% CI) p-value N OR (95% CI) p-value  p_trend 
Menarche                         
≥ 15 years   206 209 1.00 (referent)   196 1.00 (referent)   201 1.00 (referent)    
14 years   236 263 1.11 (0.85, 1.14) 0.45 244 1.07 (0.82, 1.41) 0.60 226 0.96 (0.73, 1.26) 0.76 0.49 
13 years   302 253 0.85 (0.65, 1.10) 0.22 262 0.96 (0.74, 1.25) 0.75 254 0.94 (0.72, 1.22) 0.65 0.99 
≤ 12 years   450 401 0.96 (0.75, 1.22) 0.75 384 1.01 (0.78, 1.29) 0.96 410 1.10 (0.86, 1.41) 0.44 0.30 
                         
Parity                        
Parous   1119 1011 1.00 (referent)   976 1.00 (referent)   950 1.00 (referent)    
Nulliparous   158 183 1.29 (1.03, 1.64) 0.03 175 1.30 (1.03, 1.65) 0.03 190 1.54 (1.22, 1.95) <0.0001 0.001 
                         
BMI                        
< 25 kg/m
2
   483 477 1.00 (referent)   411 1.00 (referent)   412 1.00 (referent)    
25-30 kg/m
2
   504 418 0.79 (0.65, 0.95) 0.01 408 0.87 (0.72, 1.05) 0.16 419 0.86 (0.72, 1.05) 0.14 0.53 
>30 kg/m
2
   256 250 0.86 (0.69, 1.07) 0.18 288 1.05 (0.85, 1.31) 0.64 285 0.99 (0.79, 1.24) 0.93 0.67 
                         
Combined HT use                         
Never   151 192 1.00 (referent)   269 1.00 (referent)   273 1.00 (referent)    
Former   37 34 0.96 (0.57, 1.62) 0.88 35 0.81 (0.48, 1.36) 0.43 23 0.65 (0.37, 1.16) 0.14 0.12 
Current   72 78 1.11 (0.74, 1.66) 0.60 56 0.66 (0.43, 1.00) 0.05 51 0.68 (0.44, 1.05) 0.09 0.03 
                         
Family history                        
No   907 923 1.00 (referent)   940 1.00 (referent)   959 1.00 (referent)    
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          Parity    Obesity    Combined HT 
          Nulliparous vs parous   Obese vs normal   Current vs never 
Subtype N KI67 Grade   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value 
                          
Controls 11,475       1.00 (referent)     1.00 (referent)     1.00 (referent)   
1 102 Q1 Low   0.74 (0.38, 1.44) 0.38   0.98 (0.53, 1.80) 0.94   3.88 (2.14, 7.04) <0.0001 
2 155 Q2 Low   1.56 (1.03, 2.42) 0.03   0.75 (0.46, 1.21) 0.24   2.91 (1.72, 4.92) <0.0001 
3 123 Q3 Low   1.68 (1.05, 2.69) 0.03   0.88 (0.52, 1.49) 0.63   2.08 (1.14, 3.80) 0.017 
4 79 Q4 Low   2.16 (1.24, 3.74) 0.006   0.93 (0.49, 1.77) 0.83   2.77 (1.41, 5.44) 0.003 
5 300 Q1 High   0.84 (0.57, 1.14) 0.35   1.14 (0.83, 1.58) 0.41   1.13 (0.74, 1.73) 0.56 
6 370 Q2 High   1.19 (0.88, 1.62) 0.25   1.30 (0.97, 1.76) 0.08   1.69 (1.19, 2.42) 0.004 
7 451 Q3 High   1.28 (0.97, 1.69) 0.08   1.80 (1.35, 2.39) <0.0001   1.20 (0.84, 1.72) 0.29 
8 553 Q4 High   1.37 (1.07, 1.76) 0.01   1.48 (1.14, 1.93) 0.003   1.26 (0.91, 1.77) 0.16 
                          
KI67*         1.19 (1.01, 1.39) 0.04   1.09 (0.93, 1.27) 0.22   0.95 (0.79, 1.15) 0.51 
Grade**         0.75 (0.51, 1.11) 0.12   1.63 (1.08, 2.46) 0.03   0.47 (0.30, 0.74) 0.008 
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